8226; Re-establish companion diagnostics collaborations with biopharmaceutical companies. It is not for sale in North America. & 8226; HTG EdgeSeq DLBCL Cell of Origin Assay. DNA protection probes are labeled with sequencing adaptors and tags in a thermocycler. 9 & & • No cDNA synthesis. As a practical matter, clearance often takes longer, and clearance is never assured. The IVDD specifies "essential requirements" that all medical devices must meet. Our VERI/O service laboratory was announced in June 2016. Alternatively, capital may not be available to us on favorable terms, or if at all. At the same time, however, we must carefully manage the introduction of new products. These products may be used by customers for diagnostic purposes in Europe. We face significant competition in the life sciences research and diagnostics markets. Payments under the instruments governing our indebtedness may reduce our working capital. For example, the Tax Act enacted many significant changes to the U.S. tax laws. A lack of future taxable income would adversely affect our ability to utilize these NOLs. The PMA and 510(k) clearance processes can be expensive, time-consuming and uncertain. 8226; The patents of others may have an adverse effect on our business. & We may not be able to obtain these licenses at a reasonable cost, if at all. 50 & We do not intend to pay dividends on our common stock in the foreseeable future. & Any return to stockholders will therefore be limited to the appreciation of their stock.